Celltrion Healthcare Showcases Positive Data on Switching and Monotherapy With Remsima® SC in Patients With Inflammatory Bowel Disease at UEG Week Virtual 2021
Retrieved on:
Sunday, October 3, 2021
Managed Care, Pharmaceutical, Health, Clinical Trials, Pharmacokinetics, IBD, UC, SC, Celltrion, Patient, IV, Infliximab, UEG, IQR, United European Gastroenterology, Ulcerative colitis, Health care, Inflammatory bowel disease, CD, Pharmaceutical industry, Medical imaging, inflammatory bowel disease, CT-P13 (biosimilar infliximab), Remsima® (CT-P13) intravenous (IV) formulation7, Remsima® CT-P13 subcutaneous (SC) formulation, Celltrion Healthcare, INFLAMMATORY BOWEL DISEASE, CT-P13 (BIOSIMILAR INFLIXIMAB), REMSIMA® (CT-P13) INTRAVENOUS (IV) FORMULATION7, REMSIMA® CT-P13 SUBCUTANEOUS (SC) FORMULATION, CELLTRION HEALTHCARE
Celltrion Healthcare today announced two data sets relating to the use of the subcutaneous formulation of infliximab, Remsima SC (CT-P13 SC), in inflammatory bowel disease (IBD) at a poster presentation at United European Gastroenterology (UEG) Week 2021, held virtually from October 3- 5.
Key Points:
- Celltrion Healthcare today announced two data sets relating to the use of the subcutaneous formulation of infliximab, Remsima SC (CT-P13 SC), in inflammatory bowel disease (IBD) at a poster presentation at United European Gastroenterology (UEG) Week 2021, held virtually from October 3- 5.
- The proportion of patients with Ctrough exceeding target exposure (5 g/mL) was significantly higher post-switch (36/41, 87.80%) than pre-switch (8/41, 19.51%; p
- Infliximab SC offers patients and caregivers the possibility of more convenient care with the potential for in-home use.
- Switching from intravenous to subcutaneous infliximab in patients with active inflammatory bowel disease: Post-hoc analysis of pre-/post- switch outcomes from a multicentre, randomised controlled pivotal trial.